stockmarketproxy
/
TGTXNasdaq SEC EDGAR

TG THERAPEUTICS, INC.

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1001316
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$616.3M$329.0M$233.7M$2.8M$6.7M
Gross Profit——————
Operating Income$123.3M$41.9M$20.6M-$192.8M-$344.8M
Net Income$447.2M$23.4M$12.7M——
Operating CF-$24.8M-$40.5M-$31.4M-$176.2M-$295.6M
Capex$214.0K$45.0K$0$14.0K$401.0K
Free Cash Flow-$25.0M-$40.6M-$31.4M-$176.2M-$296.0M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin20.0%12.7%8.8%-6924.2%-5154.3%
Net Margin72.6%7.1%5.4%——
FCF Margin-4.1%-12.3%-13.4%-6326.2%-4425.7%
R&D / Revenue26.0%28.7%32.6%4501.0%3327.5%
Effective Tax-316.4%8.6%3.0%0.0%0.0%
Debt / Equity0.381.101.25——
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
TGTX
67:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
TGTX
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
TGTX
72.6%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%